【佳學(xué)基因檢測(cè)】在新的全身治療線之前、期間和之后循環(huán)轉(zhuǎn)移性乳腺癌中的 miR-200 家族和 CTC

基因治療腫瘤要多少錢(qián)—爭(zhēng)論

與同行交流時(shí)發(fā)現(xiàn)《Int J Mol Sci》在.?2022 Aug 23;23(17):9535.發(fā)表了一篇題目為《在新的全身治療線之前、期間和之后循環(huán)轉(zhuǎn)移性乳腺癌中的 miR-200 家族和 CTC》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Chiara Fischer,?Andrey Turchinovich,?Manuel Feisst,?Fabian Riedel,?Kathrin Ha?denteufel,?Philipp Scharli,?Andreas D Hartkopf,?Sara Y Brucker,?Laura Michel,?Barbara Burwinkel,?Andreas Schneeweiss,?Markus Wallwiener,?Thomas M Deutsch?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

四氯化碳,急救人員, MBC,循環(huán)微小RNA,循環(huán)腫瘤細(xì)胞,上皮間質(zhì)轉(zhuǎn)化,轉(zhuǎn)移性乳腺癌, miR-200 家族, miR-200, microRNA-200 家族

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

細(xì)胞外循環(huán) microRNA (miR)-200 調(diào)節(jié)上皮間質(zhì)轉(zhuǎn)化，因此在轉(zhuǎn)移性級(jí)聯(lián)反應(yīng)中發(fā)揮重要作用，并已證明其自身是轉(zhuǎn)移性乳腺癌 (MBC) 中一種有前途的預(yù)后和預(yù)測(cè)生物標(biāo)志物。分析血漿 miR-200 家族的表達(dá)水平與全身治療、循環(huán)腫瘤細(xì)胞 (CTC) 計(jì)數(shù)、無(wú)進(jìn)展生存期 (PFS) 和總生存期 (總生存期) 的關(guān)系。在基線 (BL) 后評(píng)估了 47 名患者的 miR-200a、miR-200b、miR-200c、miR-141 和 miR-429 的表達(dá)以及 CTC 狀態(tài)（CTC 陽(yáng)性 ≥ 5 CTC/7.5 mL）。新的全身治療線（1C）的先進(jìn)個(gè)完整周期，以及疾病進(jìn)展（PD）。與 BL 相比，miR-200a、miR-200b 和 miR-141 的表達(dá)在 1C 時(shí)降低。 PD 后，與 1C 相比，所有 miR-200 均上調(diào)。在所有時(shí)間點(diǎn)，CTC 陽(yáng)性與 CTC 陰性患者的 miR-200 水平均升高。此外，升高的 miR-200s 表達(dá)和陽(yáng)性 CTC 狀態(tài)與 BL 和 1C 較差的 總生存期 相關(guān)。在 MBC 患者中，循環(huán) miR-200 家族成員在一個(gè)新的全身治療周期后減少，在 PD 期間升高，并指示 CTC 狀態(tài)。值得注意的是，miR-200 水平升高和 CTC 計(jì)數(shù)升高與較差的 總生存期 和 PFS 相關(guān)。因此，兩者都是優(yōu)化 MBC 臨床管理的有前途的生物標(biāo)志物。急救人員； MBC;循環(huán)微小RNA；循環(huán)腫瘤細(xì)胞；上皮間質(zhì)轉(zhuǎn)化；轉(zhuǎn)移性乳腺癌； miR-200 家族； miR-200； microRNA-200 家族。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-200 family were analyzed in relationship to systemic treatment, circulating tumor cells (CTC) count, progression-free survival (PFS), and overall survival (OS). Expression of miR-200a, miR-200b, miR-200c, miR-141, and miR-429, and CTC status (CTC-positive ≥ 5 CTC/7.5 mL) was assessed in 47 patients at baseline (BL), after the first completed cycle of a new line of systemic therapy (1C), and upon the progression of disease (PD). MiR-200a, miR-200b, and miR-141 expression was reduced at 1C compared to BL. Upon PD, all miR-200s were upregulated compared to 1C. At all timepoints, the levels of miR-200s were elevated in CTC-positive versus CTC-negative patients. Further, heightened miR-200s expression and positive CTC status were associated with poorer OS at BL and 1C. In MBC patients, circulating miR-200 family members decreased after one cycle of a new line of systemic therapy, were elevated during PD, and were indicative of CTC status. Notably, increased levels of miR-200s and elevated CTC count correlated with poorer OS and PFS. As such, both are promising biomarkers for optimizing the clinical management of MBC.Keywords:?CTC; EMT; MBC; circulating microRNA; circulating tumor cells; epithelial-mesenchymal transition; metastatic breast cancer; miR-200 family; miR-200s; microRNA-200 family.